|
시장보고서
상품코드
1786996
세계의 듀피젠트 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 적응증별, 유통채널별, 지역별 예측(2025-2034년)Dupixent Market Size, Share, Trends, Industry Analysis Report By Indication [Atopic Dermatitis (AD), Asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)], By Distribution Channel, By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 세계의 듀피젠트 시장 규모는 2034년까지 287억 달러에 이를 것으로 예측됩니다. 이 조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.
듀피젠트 시장은 2형 염증에 관여하는 특정 단백질을 표적으로 하는 생물학적 제제인 두필루맙의 세계 상업 상황을 말합니다. 이 시장은 두필루맙의 연구개발부터 제조, 유통, 판매, 궁극적으로 환자의 사용에 이르기까지 모든 측면을 포함합니다. 듀피젠트는 주로 중등도에서 중증의 아토피 피부염, 천식, 비용종을 동반한 만성 코 부비동염, 호산구성 식도염, 결절성 가려움증, 만성 폐색성 폐 질환의 일종 등 다양한 만성 염증성 질환의 치료에 사용되는 처방전 전용 약물입니다. 이 시장은 제약 회사, 건강 관리 제공업체 및 이 고급 치료의 혜택을 받는 환자를 포함한 밸류체인 전체를 포함합니다.
듀피젠트 시장은 2형 염증에 대한 이해가 깊어지고 관련 만성질환의 치료에 있어 큰 미충족 요구에 의해 큰 성장과 진화를 이루고 있습니다. 듀피젠트는 당초 아토피 피부염을 적응증으로 승인했지만, 그 후 다양한 적응증과 연령층에서 승인된 것이 시장 확대에 크게 영향을 주어 범용성이 높은 치료 옵션이 되고 있습니다. 듀피젠트의 작용기전은 인터루킨-4(IL-4)와 인터루킨-13(IL-13) 경로의 신호전달을 저해하는 것이며, 기존 치료법과는 차별화되고, 이러한 복잡한 병태를 관리하기 위한 겨냥한 접근을 제공합니다. 이 때문에 처방의사와 환자 모두로부터 높은 지지를 얻고 있어 세계의 의약품 시장에 있어서의 듀피젠트의 존재감을 높이고 있습니다.
듀피젠트 시장 보고서 하이라이트
적응증별로는 아토피 피부염(AD)이 2024년 최대 점유율을 차지했습니다. 아토피 피부염은 널리 만연하고 있으며, 듀피젠트는 경증에서 중증의 아토피 피부염에 대한 효능을 확립하고 있기 때문에 동 시장에서 주도적인 지위와 지속적인 수요가 확보되고 있습니다.
유통 채널별로 2024년 듀피젠트 유통에서 가장 큰 점유율을 차지한 것은 병원 약국이었습니다. 이는 주로 듀피젠트가 특수한 생물학적 제제이기 때문에 초기 투여나 면밀한 모니터링을 병원 내에서 실시해야 하는 경우가 많고, 의료 전문가가 그 특수한 취급이나 환자 교육의 필요성을 관리할 수 있는 체제를 갖추고 있기 때문입니다.
지역별로는 북미가 듀피젠트 시장을 선도하고 있습니다. 이러한 이점은 고급 건강 관리 인프라, 혁신적인 생물학적 제형에 대한 높은 인지도와 수용성, 유리한 상환 정책, 2형 염증성 질환을 앓고 있는 환자 수가 많음 등에 기인합니다. 아시아태평양은 시장에 역동적이고 고성장 지역으로 급부상하고 있습니다. 이 성장은 건강 관리 인프라 개선, 가처분 소득 증가, 만성 염증성 질환에 대한 고급 치료 옵션에 대한 의식 증가 등 여러 요인에 의해 추진되고 있습니다.
이 시장의 주요 기업으로는 Sanofi, Regeneron Pharmaceuticals 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 듀피젠트 세계 시장 인사이트
- 시장 현황
- 듀피젠트 시장 역학
- 파이프라인 분석
- 시장 집중도와 특징
- 성장 촉진요인과 기회
- 2형 염증성 질환의 유병률의 상승
- 승인 적응증 및 연령층 확대
- 성장 억제요인과 과제
- 고액의 치료비
- 성장 촉진요인과 기회
- PESTEL 분석
- 듀피젠트 시장 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계 듀피젠트 시장 : 적응증별
- 주요 조사 결과
- 소개
- 아토피 피부염(AD)
- 천식
- 비용종을 동반한 만성 부비동염(CRSwNP)
- 만성 폐색성 폐질환(COPD)
- 기타
제6장 세계의 듀피젠트 시장 : 유통 채널별
- 주요 조사 결과
- 소개
- 병원 약국
- 소매 약국
- 기타
제7장 세계 듀피젠트 시장 : 지역별
- 주요 조사 결과
- 소개
- 듀피젠트 시장 평가 : 지역별, 2020-2034년
- 북미
- 북미 : 적응증별, 2020-2034년
- 북미 : 유통 채널별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 적응증별, 2020-2034년
- 유럽 : 유통 채널별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 적응증별, 2020-2034년
- 아시아태평양 : 유통 채널별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 적응증별, 2020-2034년
- 중동 및 아프리카 : 유통 채널별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 적응증별, 2020-2034년
- 라틴아메리카 : 유통 채널별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제8장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제9장 기업 프로파일
- Regeneron Pharmaceuticals
- Sanofi
The global dupixent market size is expected to reach USD 28.70 billion by 2034, according to a new study by Polaris Market Research. The report "Dupixent Market Size, Share, Trends, Industry Analysis Report By Indication [Atopic Dermatitis (AD), Asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)], By Distribution Channel, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The Dupixent market refers to the global commercial landscape for dupilumab, a biologic medication that targets specific proteins involved in type 2 inflammation. This market includes all aspects from the research and development of dupilumab to its manufacturing, distribution, and sale, and ultimately its use by patients. Dupixent is a prescription-only medication primarily used to treat a range of chronic inflammatory conditions, including moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and a specific type of chronic obstructive pulmonary disease. The market encompasses the entire value chain, involving pharmaceutical companies, healthcare providers, and the patients who benefit from this advanced therapy.
The Dupixent market has seen considerable growth and evolution, driven by the increasing understanding of type 2 inflammation and the significant unmet needs in treating associated chronic diseases. Initially approved for atopic dermatitis, Dupixent's market expansion has been greatly influenced by its subsequent regulatory approvals across various indications and age groups, making it a versatile treatment option. Its mechanism of action, which involves inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, differentiates it from traditional treatments and offers a targeted approach to managing these complex conditions. This has led to strong adoption among both prescribers and patients, contributing to its substantial presence in the global pharmaceutical landscape.
Dupixent Market Report Highlights
By indication, the atopic dermatitis (AD) segment held the largest share in 2024. Its widespread prevalence and Dupixent's established efficacy in treating moderate-to-severe forms of this chronic skin condition have ensured its leading position and continued demand within the market.
By distribution channel, the hospital pharmacies segment held the largest share in 2024 in Dupixent distribution. This is primarily because Dupixent, as a specialized biologic, often requires initial administration or close monitoring in a hospital setting, where healthcare professionals are equipped to manage its specific handling and patient education needs.
By region, North America is leading in the Dupixent market. This dominance is driven by its advanced healthcare infrastructure, high awareness and acceptance of innovative biologic therapies, favorable reimbursement policies, and a significant patient population suffering from type 2 inflammatory diseases. Asia Pacific is rapidly emerging as a dynamic and high-growth region for the market. This growth is propelled by several factors, including improving healthcare infrastructure, rising disposable incomes, and increasing awareness of advanced treatment options for chronic inflammatory diseases.
Key players in the market include Sanofi and Regeneron Pharmaceuticals.
Polaris Market Research has segmented the Dupixent market report based on indication, distribution channel, and region:
By Indication Outlook (Revenue - USD Billion, 2020-2034)
Atopic Dermatitis (AD)
Asthma
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Chronic Obstructive Pulmonary Disease (COPD)
Others
By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)
Hospital Pharmacies
Retail Pharmacies
Others
By Regional Outlook (Revenue - USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Dupixent Market Insights
- 4.1. Dupixent Market - Market Snapshot
- 4.2. Dupixent Market Dynamics
- 4.3. Pipeline Analysis
- 4.4. Market Concentration & Characteristics
- 4.4.1. Drivers and Opportunities
- 4.4.1.1. Rising Prevalence of Type 2 Inflammatory Diseases
- 4.4.1.2. Broadening of Approved Indications and Age Groups
- 4.4.2. Restraints and Challenges
- 4.4.2.1. High treatment costs
- 4.4.1. Drivers and Opportunities
- 4.5. Porter's Five Forces Analysis
- 4.5.1. Bargaining Power of Suppliers (Moderate)
- 4.5.2. Threats of New Entrants: (Low)
- 4.5.3. Bargaining Power of Buyers (Moderate)
- 4.5.4. Threat of Substitute (Moderate)
- 4.5.5. Rivalry among existing firms (High)
- 4.6. PESTEL Analysis
- 4.7. Dupixent Market Trends
- 4.8. Value Chain Analysis
- 4.9. COVID-19 Impact Analysis
5. Global Dupixent Market, by Indication
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 5.3. Atopic Dermatitis (AD)
- 5.3.1. Global Dupixent Market, by Atopic Dermatitis (AD), by Region, 2020-2034 (USD Billion)
- 5.4. Asthma
- 5.4.1. Global Dupixent Market, by Asthma, by Region, 2020-2034 (USD Billion)
- 5.5. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
- 5.5.1. Global Dupixent Market, by Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), by Region, 2020-2034 (USD Billion)
- 5.6. Chronic Obstructive Pulmonary Disease (COPD)
- 5.6.1. Global Dupixent Market, by Chronic Obstructive Pulmonary Disease (COPD), by Region, 2020-2034 (USD Billion)
- 5.7. Others
- 5.7.1. Global Dupixent Market, by Others, by Region, 2020-2034 (USD Billion)
6. Global Dupixent Market, by Distribution Channel
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 6.3. Hospital Pharmacies
- 6.3.1. Global Dupixent Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
- 6.4. Retail Pharmacies
- 6.4.1. Global Dupixent Market, by Retail Pharmacies, by Region, 2020-2034 (USD Billion)
- 6.5. Others
- 6.5.1. Global Dupixent Market, by Others, by Region, 2020-2034 (USD Billion)
7. Global Dupixent Market, by Geography
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Dupixent Market Assessment, By Geography, 2020-2034 (USD Billion)
- 7.3. Dupixent Market - North America
- 7.3.1. North America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.3.2. North America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.3.3. Dupixent Market - U.S.
- 7.3.3.1. U.S.: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.3.3.2. U.S.: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.3.4. Dupixent Market - Canada
- 7.3.4.1. Canada: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.3.4.2. Canada: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4. Dupixent Market - Europe
- 7.4.1. Europe: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.4.2. Europe: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.3. Dupixent Market - UK
- 7.4.3.1. UK: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.4.3.2. UK: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.4. Dupixent Market - France
- 7.4.4.1. France: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.4.4.2. France: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.5. Dupixent Market - Germany
- 7.4.5.1. Germany: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.4.5.2. Germany: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.6. Dupixent Market - Italy
- 7.4.6.1. Italy: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.4.6.2. Italy: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.7. Dupixent Market - Spain
- 7.4.7.1. Spain: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.4.7.2. Spain: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.8. Dupixent Market - Netherlands
- 7.4.8.1. Netherlands: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.4.8.2. Netherlands: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.9. Dupixent Market - Russia
- 7.4.9.1. Russia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.4.9.2. Russia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.10. Dupixent Market - Rest of Europe
- 7.4.10.1. Rest of Europe: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.4.10.2. Rest of Europe: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5. Dupixent Market - Asia Pacific
- 7.5.1. Asia Pacific: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.5.2. Asia Pacific: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.3. Dupixent Market - China
- 7.5.3.1. China: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.5.3.2. China: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.4. Dupixent Market - India
- 7.5.4.1. India: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.5.4.2. India: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.5. Dupixent Market - Malaysia
- 7.5.5.1. Malaysia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.5.5.2. Malaysia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.6. Dupixent Market - Japan
- 7.5.6.1. Japan: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.5.6.2. Japan: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.7. Dupixent Market - Indonesia
- 7.5.7.1. Indonesia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.5.7.2. Indonesia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.8. Dupixent Market - South Korea
- 7.5.8.1. South Korea: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.5.8.2. South Korea: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.9. Dupixent Market - Australia
- 7.5.9.1. Australia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.5.9.2. Australia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.10. Dupixent Market - Rest of Asia Pacific
- 7.5.10.1. Rest of Asia Pacific: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.5.10.2. Rest of Asia Pacific: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.6. Dupixent Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.6.2. Middle East & Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.6.3. Dupixent Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.6.3.2. Saudi Arabia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.6.4. Dupixent Market - UAE
- 7.6.4.1. UAE: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.6.4.2. UAE: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.6.5. Dupixent Market - Israel
- 7.6.5.1. Israel: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.6.5.2. Israel: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.6.6. Dupixent Market - South Africa
- 7.6.6.1. South Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.6.6.2. South Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.6.7. Dupixent Market - Rest of Middle East & Africa
- 7.6.7.1. Rest of Middle East & Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.6.7.2. Rest of Middle East & Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.7. Dupixent Market - Latin America
- 7.7.1. Latin America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.7.2. Latin America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.7.3. Dupixent Market - Mexico
- 7.7.3.1. Mexico: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.7.3.2. Mexico: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.7.4. Dupixent Market - Brazil
- 7.7.4.1. Brazil: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.7.4.2. Brazil: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.7.5. Dupixent Market - Argentina
- 7.7.5.1. Argentina: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.7.5.2. Argentina: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.7.6. Dupixent Market - Rest of Latin America
- 7.7.6.1. Rest of Latin America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.7.6.2. Rest of Latin America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Regeneron Pharmaceuticals
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Sanofi
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
